HortenseFouilland

Associate

Paris + 33.1.56.59.38.76

Connect:

Share

Hortense Fouilland's practice focuses on venture capital, private equity, M&A, and capital markets. She assists high-growth companies, both listed and unlisted, their managers, and private equity and industrial investors in all operations and at every stage of development, from entrepreneurial start-ups to global corporations. She also has experience in mid-cap and large-cap leveraged buyout (LBO) transactions.

Experience

  • ManoMano completes $355 million Series F financing roundJones Day represented ManoMano, an online marketplace specializing in the sale of DIY, home improvement, and gardening products, in connection with its $355 million Series F round of financing led by Dragoneer Investment Group with the participation of existing investors Temasek, General Atlantic, Eurazeo, Bpifrance, Aglaé Ventures, Kismet Holdings, and Armat Group.
  • Elaia Partners leads €4 million financing round of Mablink BioscienceJones Day represented Elaia Partners in connection with the €4 million seed round of financing of Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform.
  • Unseenlabs raises €20 million in Series B funding roundJones Day advised Unseenlabs, a European leader in satellite radio frequency (RF) geolocation of ships at seas, in connection with its €20 million Series B round of financing.
  • HealthHero acquires QareJones Day advised HealthHero in its acquisition of Qare, a French platform that provides medical video consultation services, backed by Kamet Ventures.
  • Nanobiotix completes $113.3 million IPO on NasdaqJones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.
  • IntegraGen’s shareholders sell majority interest to OncoDNA in tender offerJones Day advised IntegraGen, a biotechnology company developing molecular markers for central nervous system and metabolic diseases, in connection with the public tender offer of shares by OncoDNA, a private health technology and precision medicine company focused on oncology.
  • Elaia Partners participates in €2 million financing of Honing BiosciencesJones Day represented Elaia Partners in connection with the €2 million financing of Honing Biosciences, a French bio-therapeutics company that develops and improves cell-based therapies.
  • European growth VC investor participates in €12.5 million financing round of AlmaJones Day assisted a European growth VC investor in connection with the €12.5 million financing round of Alma, a French fintech which simplified installment payments for e-commerce and in-store merchants.
  • Pharnext raises €7.7 million in private placementJones Day represented Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, in connection with its €7.7 million private placement of 1,799,061 of new Ordinary Shares.
  • Tinubu® Square acquires U.S. company eSURETY®Jones Day advised Tinubu® Square in its acquisition of U.S.-based eSURETY®, a cloud-based specialty software provider, enabling carriers, brokers, and MGAs to securely apply, quote, bond, issue, and support every form of surety as well as offering a powerful direct-to-the-consumer experience on any device from any browser, anywhere in the world.
  • Carrefour acquires Potager CityJones Day advised Carrefour Group in its acquisition of Potager City, a French distributor of online subscription-based boxes of extra-fresh and seasonal fruit and vegetables sourced via short distribution channels.
  • Valar Ventures and Alven Capital participate in €104 million Series C financing round of QontoJones Day assisted Valar Ventures and Alven Capital in connection with the €104 million Series C round of financing of Qonto, the neobank for SMEs and freelancers, which included China-based Tencent and DST Global as two new global investors.
  • Alven Capital invests in CardiologsJones Day represented Alven Capital SA in connection with its investment in Cardiologs, a company engaged in the development of an AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities.
  • Macquarie Infrastructure and Real Assets to divest stakes in Autoroutes Paris-Rhin-RhoneJones Day is advising Macquarie Infrastructure and Real Assets (Europe) Limited in the sale by subsidiaries Macquarie Infrastructure Fund 2, Macquarie Mercer Infrastructure Trust 1, and Macquarie Mercer Infrastructure Trust 2 of remaining stakes in Autoroutes Paris-Rhin-Rhone for an aggregate price of €867 million, subject to timing of completion.
  • Cyrus Capital Partners acquires, in French insolvency proceeding, of French business of Toys R UsJones Day represented Cyrus Capital Partners in connection with the acquisition, in a French insolvency proceeding, of the French business (comprised notably of 44 stores) of Toys R Us.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.